AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ELAN · NYSE · Drug Manufacturers - Specialty & Generic

Elanco Animal Health (ELAN)

Develops medicines, vaccines, and feed products for pets and farm animals.

$23.09

vs last close+0.66 (+2.94%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	1,068	1,035	1,205	1,184	1,030	1,020	1,193	1,241	1,137	1,144	1,371	1,368
Cost of revenue	627	654	648	626	625	631	637	664	530	694	586	570
Gross profit	441	381	557	558	405	389	556	577	607	450	785	798
	399	371	424	443	410	381	435	492	580	431	478	689
Research & development	86	79	87	89	87	81	94	92	89	93	97	92
	313	292	337	354	323	300	341	400	351	338	381	449
Selling & marketing	0	0	0	0	0	0	0	0	0	0	0	449
General & administrative	0	0	0	0	0	0	0	0	351	0	0	0
Other expenses	0	0	0	0	0	0	0	0	140	0	0	148
Operating income	42	10	133	115	−5	8	121	85	27	19	307	109
	−1,139	−137	−121	−147	564	−59	−61	−60	−77	−278	−220	−53
Interest income	0	0	0	0	0	0	0	11	0	11	0	0
Interest expense	72	67	66	65	85	62	53	70	52	91	57	59
Other non-operating income	1,067	70	55	82	−649	−3	8	−10	25	187	163	6
Income before tax	−1,097	−127	12	−32	559	−51	60	25	−50	−259	87	56
Income tax expense	−1	14	−20	18	195	−43	−7	14	−16	17	30	2
Net income from continuing operations	−1,096	−141	32	−50	364	−8	67	11	−34	−276	57	54
Net income	−1,096	−141	32	−50	364	−8	67	11	−34	−276	57	54
EPS, basic	−$2.22	−$0.29	$0.06	−$0.10	$0.74	−$0.02	$0.14	$0.02	−$0.07	−$0.56	$0.11	$0.11
EPS, diluted	−$2.22	−$0.29	$0.06	−$0.10	$0.73	−$0.02	$0.13	$0.02	−$0.07	−$0.55	$0.11	$0.11
Weighted average shares, basic	493	493	493	494	494	494	495	497	497	497	498	500
Weighted average shares, diluted	493	493	496	494	498	494	499	500	497	497	506	506
EBITDA	−852	111	244	195	814	175	274	264	178	6	316	274
Depreciation & amortization	173	171	166	162	170	164	161	169	176	174	172	171
EBIT	−1,025	−60	78	33	644	11	113	95	2	−168	144	103